Day: February 27, 2024

To NASDAQ Copenhagen A/S                                                                                                                  27 February 2024                                                                                                                 Announcement no. 19/2024 Annual Report of Jyske Realkredit A/S for the financial year 2023 On February 27, 2024, the Board of Directors has approved the Annual Report of Jyske Realkredit A/S for the financial year 2023. Please see attached files. Yours sincerely,Jyske Realkredit A/S Carsten Tirsbæk MadsenCEO Direct phone (+45) 89 89 90 50E-mail ctm@jyskerealkredit.dk Web: jyskerealkredit.com Please observe that the Danish version of this announcement prevails. Attached files:Jyske Realkredit Preliminary announcement of financial statements 2023.pdfJyske Realkredit Annual Report...

The Supervisory Board of AS LHV Group approved the 2023 audited annual report and will submit it to the Annual General Meeting for approval. Compared to the unaudited interim report published on 6 February, there are no differences in the audited financial results. The 2023 consolidated annual report of LHV Group is attached to this notice and will be made available on the LHV Group investor page at https://investor.lhv.ee/en/reports/#annual-reports. LHV Group generated consolidated revenues of EUR 310.5 million (+79%) in 2023. Of the revenue, net interest income accounted for EUR 253.8 million (+97%), and net fee and commission income EUR 54.1 million (+21%). The expenses of the consolidation group in 2023 amounted to EUR 134.3 million (+50%). The consolidated net profit of LHV Group in 2023 amounted to EUR 140.9 million, i.e., 129% more...

Press release  Pluxee successfully places a €1.1 billion bonds issue Paris: February 27, 2024 // Pluxee (the ‘’Group’’), announced today that it successfully placed two inaugural bonds for an aggregate amount of EUR 1.1 billion, consisting of a EUR 550 million bond issue with a 4.5-year maturity with a coupon of 3.50% and a EUR 550 million bond issue with a 8.5-year maturity with a coupon of 3.75%. The net proceeds of this bonds issue will be allocated to general corporate purposes of the Group, including the refinancing of part of the existing bridge loan of €1.5 billion entered into by Pluxee with a syndicate of international banks in connection with its spin-off from Sodexo and listing on the regulated market of Euronext Paris. Application will be made to admit the bonds to trading on the regulated market of Euronext in Paris...

Company Announcement – No. 10 / 2024 Zealand Pharma convenes its Annual General Meeting 2024 Notice to convene the Annual General Meeting of Zealand Pharma A/S (CVR no. 20 04 50 78) (the “Company”). The Board of Directors of the Company hereby convenes the Annual General Meeting of the Company to be held on: Wednesday, March 20, 2024 at 3:00 pm (CEST) The Annual General Meeting will be held as a partly electronic general meeting with the possibility of attending electronically or in person (hybrid meeting). The Annual General Meeting will be held electronically via the virtual portal hosted by Computershare A/S, and physically at the Company’s registered address Sydmarken 11, DK-2860 Søborg. Please find further information in the accompanying attachment.AttachmentZealand Pharma_AGM 2024 Notice ...

The Management Board of AS LHV Group (hereinafter LHV Group) hereby calls the general meeting of the shareholders (hereinafter the General Meeting), to be held on 20 March 2024 starting at 13:00 (Estonian time) at Hilton Tallinn Park Hotel (Fr. R Kreutzwaldi 23, Tallinn). The list of shareholders entitled to participate in the General Meeting will be determined as of 7 (seven) days before the General Meeting, i.e., as at 13 March 2024 EOD of Nasdaq CSD settlement system. Pursuant to the resolution adopted by LHV Group’s Supervisory Board on 21 February 2024, the agenda of the General Meeting will be following, and the proposals of the Management Board and the Supervisory Board in regard to the agenda items are specified by each agenda item as follows, whereas the Supervisory Board has proposed to vote in favour of all draft resolutions...

Naples Florida, Feb. 27, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading company in the music licensing industry, is taking proactive measures to address a targeted false narrative campaign circulating on social media platforms. Recently, there has been a surge in misleading and false information regarding Music Licensing, Inc. and its management team being spread on various social media channels and chat rooms. These false claims aim to sow doubt and confusion among shareholders and the public. Music Licensing, Inc. categorically denies all baseless allegations and false narratives being circulated. The company’s management team is committed to transparency and adhering to the highest standards of corporate governance. In response to these malicious attacks, Music Licensing, Inc. advises shareholders...

VANCOUVER, British Columbia, Feb. 26, 2024 (GLOBE NEWSWIRE) — Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) announces that it will release its financial statements and MD&A for the fourth quarter and full year 2023 on Wednesday, March 6, 2024, after the market closes. A conference call to discuss the financial and operational results will be held on Thursday, March 7, 2024, at 9:00 a.m. Pacific time | 12:00 p.m. Eastern time. Hosting the call will be Jorge A. Ganoza, President and CEO, Luis D. Ganoza, Chief Financial Officer, Cesar Velasco, Chief Operating Officer – Latin America, and David Whittle, Chief Operating Officer – West Africa. Shareholders, analysts, media and interested investors are invited to listen to the live conference call by logging onto the webcast at: https://www.webcaster4.com/Webcast/Page/1696/49929...

Media Release COPENHAGEN, Denmark; February 27, 2024FDA grants Priority Review with target action date of June 28, 2024 Application based on results from Phase 1/2 EPCORE™ NHL-1 trial demonstrating clinically meaningful treatment responses in difficult-to-treat patients with relapsed or refractory (R/R) follicular lymphoma (FL) sBLA submission demonstrates Genmab’s commitment to exploring potential utility of epcoritamab across B-cell malignanciesGenmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two...